Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX – Get Rating) saw a large increase in short interest in April. As of April 30th, there was short interest totalling 209,200 shares, an increase of 60.9% from the April 15th total of 130,000 shares. Based on an average daily volume of 316,100 shares, the short-interest ratio is currently 0.7 days. Approximately 1.8% of the company’s stock are short sold.
A number of institutional investors and hedge funds have recently modified their holdings of KPRX. BlackRock Inc. bought a new position in Kiora Pharmaceuticals during the 4th quarter worth $32,000. Renaissance Technologies LLC bought a new position in Kiora Pharmaceuticals during the 1st quarter worth $58,000. Finally, Geode Capital Management LLC bought a new position in Kiora Pharmaceuticals during the 4th quarter worth $791,000. Hedge funds and other institutional investors own 29.70% of the company’s stock.
Shares of NASDAQ KPRX traded up $0.08 during trading on Friday, reaching $0.45. The stock had a trading volume of 237,026 shares, compared to its average volume of 118,070. The firm has a market capitalization of $5.67 million, a PE ratio of -0.29 and a beta of 0.94. The stock has a 50 day simple moving average of $0.58. Kiora Pharmaceuticals has a one year low of $0.35 and a one year high of $6.43.
Kiora Pharmaceuticals Company Profile (Get Rating)
Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.
- Get a free copy of the StockNews.com research report on Kiora Pharmaceuticals (KPRX)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Kiora Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiora Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.